Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 312
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01454986 | Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects | ||
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | ||
| NCT04564339 | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ||
| NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | ||
| NCT05840055 | ACT with NMOSD Patients and Caregivers Pilot Study | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab | ||
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | ||
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | ||
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype | ||
| NCT06208488 | A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants | ||
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | ||
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | ||
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT00546260 | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | ||
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | ||
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | ||
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | ||
| NCT02796885 | Characterisation of Adult-Onset Hypophosphatasia | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT00675844 | An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment | ||
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | ||
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT07337395 | Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | ||
| NCT00350272 | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants | ||
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT05982938 | Danicopan Early Access Program | ||
| NCT04970004 | Study in Adult and Pediatric Patients With HSCT-TMA | ||
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | ||
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | ||
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 |
